Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound ...

CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, expectations were $-0.14. Operator: Greetings.

CureVac (CVAC) has reported its fourth quarter 2024 financial results, generating mixed reactions from investors as the company balances ...

Financial Runway: Expected financial runway into 2028. CureVac NV (NASDAQ:CVAC) reported a strong cash position of EUR482 million at the end of 2024, providing a financial runway into 2028. The ...

Greetings. Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my ...

Greetings. Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac. We ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.